TENSE
Ultimovacs continues to deliver during the first quarter
Norwegian immuno-oncology company Ultimovacs made progress on several fronts during the first quarter. The company's clinical program with the universal cancer vaccine...
Ultimovacs advances to the final cohort in the TENDU study
Ultimovacs continues to advance its Phase I study TENDU...
Ultimovacs begins the next phase in the development of a new vaccine platform
Ultimovacs is conducting a Phase I clinical study testing...
Strengthened clinical validation of Ultimovacs UV1 in the second quarter
For Norwegian Ultimovacs, the second quarter of the year was about...
Intervju